Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.2, 2013-01, pp. : 205-213

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pharmacogenomics of Sex Difference in Chemotherapeutic Toxicity

Current Drug Discovery Technologies, Vol. 4, Iss. 1, 2007-06 ,pp. : 59-68

Bentham Science Publishers

Access to resources Recommend Favorite

Trastuzumab associated with increased risk of cardiotoxicity

Reactions Weekly, Vol. 1, Iss. 1199, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Trastuzumab-Induced Cardiotoxicity: Is it a Personalized Risk?

Current Drug Targets, Vol. 15, Iss. 13, 2014-12 ,pp. : 1200-1204

Bentham Science Publishers

Access to resources Recommend Favorite

Alternative Approach for Mitigation of Doxorubicin-Induced Cardiotoxicity using Herbal Agents

Current Clinical Pharmacology, Vol. 9, Iss. 3, 2014-08 ,pp. : 288-297

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenomics research: a potential strategy for drug development

By Wen Jia-Gen Wu Lin Pu Xin-Xiang He Fa-Zhong Liu Mou-Ze Zhou Hong-Hao Zhang Wei

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 7, 2015-07 ,pp. : 437-445

Govi-Verlag

Access to resources Recommend Favorite